FRANKFURT – With a maturing clinical pipeline and big ambitions for creating a new paradigm for translational research in Germany, Oryx GmbH & Co. KG, a company that has flown under the radar since its formation, finally set out its stall at Bio-Europe.
FRANKFURT – Big pharma's and big biotech's rapid push into cancer immunotherapy has become a major theme in the business – as well as the drug – development strategies of the main players, all of which are vying to gain an edge on their rivals.
FRANKFURT – John Kerry and Hilary Clinton are among the political luminaries due to visit Germany at the weekend, to mark the 25th anniversary of the fall of the Berlin Wall, on Nov. 9.
DUBLIN – Apogenix GmbH entered its first big pharma licensing deal, a pact with Abbvie Inc., on a preclinical TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist, APG-880, in various cancer indications.
Imevax GmbH, a newly formed spinout from the Technical University of Munich (Technische Universität München; TUM), raised €7.5 million (US$9.6 million) in a series A round to fund clinical trials of a vaccine against Helicobacter pylori.
DUBLIN – Bristol-Myers Squibb Co. is paying $50 million up front and could pay another $425 million to acquire F-Star Alpha Ltd. and its human epidermal growth factor receptor 2 (HER2)-targeted therapy, FS102.
DUBLIN – The recent reform of the notorious double-Irish tax avoidance scheme sends out a clear signal to those companies that currently avail of it, according to a senior tax policy official.
DUBLIN – Johnson & Johnson's vaccine subsidiary Crucell Holland BV and Bavarian Nordic A/S have entered a formal license and supply agreement to accelerate and scale up an ongoing collaboration with the NIH in the development of a combination Ebola virus vaccine regimen.
